BioVie Inc.
BIVIHealthcare|Biotechnology|US
$1.33
+0.12 (+9.92%)
DCF Value
$1200941.90
Tangible Book / Share
$0.75
Cash / Share
$0.94
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04669028 A Phase 3 Study of NE3107 in Probable Alzheimer's Disease | Alzheimer Disease | P3 | Completed | 439 | RCT, Double-blind | NE3107, Placebo |
| NCT05227820 Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia | Alzheimer Disease | P2 | Completed | 23 | Open-label | NE3107 |
| NCT05083260 NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa | Parkinson Disease | P1P2 | Completed | 46 | RCT, Double-blind | NE3107, placebo |
| NCT06757010 A Study of NE3107 in Early Parkinson's | Parkinsons Disease (PD) | P2 | Completed | 57 | RCT, Double-blind | NE3107, Placebo |
| NCT04112199 A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites | Ascites, Decompensated Cirrhosis | P2 | Terminated | 15 | RCT, Open-label | BIV201 continuous infusion |
| NCT06847191 NE3107 in Adults With Neurological Symptoms of Long COVID | Long COVID | P2 | Completed | 203 | RCT, Double-blind | NE3107, Placebo |
| NCT05970575 Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury | Traumatic Brain Injury | P2 | Terminated | 4 | Open-label | NE3107 |
| NCT03107091 Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites | Cirrhosis, Ascites Hepatic | P2 | Completed | 6 | Open-label | Terlipressin acetate continuous infusion |